Massimino M, Spreafico F, Luksch R, Giardini R
Pediatric Oncology Unit, Istituto Nazionale Tumori, Via G. Venezian, I-20133 Milan, Italy.
Med Pediatr Oncol. 2001 Aug;37(2):97-102. doi: 10.1002/mpo.1176.
Between 1976 and 1998, CD30+anaplastic large cell lymphoma (ALCL) was diagnosed in 44 children (28 males, 16 females, age range 2.7-16.1 years, median 10). Up to 1993, 32 such children were treated according to a common chemotherapeutic protocol that stratified patients according to stage, without considering presenting features. Thereafter, patients presenting with visceral (lung, spleen, liver, gastro-intestinal tract) or mediastinal involvement were assigned to a high-risk treatment protocol with induction intensification. The generation of these two risk-groups was the result of a retrospective analysis of clinical risk factors for therapy failure as previously reported [Massimino M, Gasparini M, Giardini R, Ann Oncol 1995;6:915-920]. Considering the whole cohort of patients divided into group A-21/22 evaluable patients with visceral/mediastinal involvement, and group B-22 evaluable patients, with other ALCL location-disease-free survival (DFS) and survival (S) at 5 years were 57 and 58% for group A, and 83 and 100% (94% at 6 years) for group B, respectively.
We tested 15/21 cases of group A, and 18/22 of group B for p80 immunoreactivity in order to investigate a possible correlation between ALCL locations and NPM-ALK expression.
Thirteen of 15 specimens in group A and 17/18 in group B were positive for p80.
It is impossible to conclude anything about p80 positivity based on a series of 33/44 patients with childhood ALCL, neither about over-all prognosis nor about the role of visceral involvement. In adults, NPM-ALK protein expression is a favourable prognostic factor. Med Pediatr Oncol 2001;37:97-102.
1976年至1998年间,44例儿童被诊断为CD30+间变性大细胞淋巴瘤(ALCL)(28例男性,16例女性,年龄范围2.7 - 16.1岁,中位数10岁)。到1993年,32例此类儿童按照一种常见的化疗方案进行治疗,该方案根据分期对患者进行分层,而不考虑临床表现。此后,出现内脏(肺、脾、肝、胃肠道)或纵隔受累的患者被分配到一个强化诱导的高风险治疗方案。这两个风险组的产生是先前报道的对治疗失败的临床风险因素进行回顾性分析的结果[马西米诺M,加斯帕里尼M,贾尔迪尼R,《肿瘤学年鉴》1995;6:915 - 920]。考虑将整个患者队列分为A组——21/22例可评估的有内脏/纵隔受累的患者,以及B组——22例可评估的患者,A组5年时无病生存率(DFS)和生存率(S)分别为57%和58%,B组分别为83%和100%(6年时为94%)。
为了研究ALCL部位与NPM-ALK表达之间可能的相关性,我们检测了A组15/21例病例和B组18/22例病例的p80免疫反应性。
A组15个标本中有13个,B组18个中有17个p80呈阳性。
基于44例儿童ALCL患者中的33例,无法就p80阳性得出任何结论,无论是关于总体预后还是内脏受累的作用。在成人中,NPM-ALK蛋白表达是一个有利的预后因素。《医学与儿科肿瘤学》2001;37:97 - 102。